| Document |
Document Title |
|
WO/2003/093248A1 |
Compounds of formula (I) are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
|
|
WO/2003/089417A1 |
The present invention relates to novel crystalline forms of (S)-N- (1-Carboxy-2methyl-prop-1-yl) -N-pentanoyl-N- [2'-(1H-tetrazol-5-yl)- biphenyl-4-yl methyl amine (Valsartan) and to processes for their preparation. Valsartan, chemical...
|
|
WO/2003/086563A2 |
The present invention relates to fluorinated or paramagnetic anti-diabetes probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions.
|
|
WO/2003/087037A1 |
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of ...
|
|
WO/2003/082205A2 |
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and so...
|
|
WO/2003/083063A2 |
The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affi...
|
|
WO/2003/082861A2 |
Compounds of formula (I) wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents -(CRnaRnb)n-; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 0 to 5;R2 represents unsubstituted or subs...
|
|
WO/2003/080564A1 |
This invention is directed to menthol-substituted compounds and their pharmaceutically acceptable salts which are useful as antithrombotic agents by inhibiting plasminogen activator inhibitor-1 (PAI-1). In addition, the present invention...
|
|
WO/2003/080042A1 |
A medicinal composition which contains a compound represented by the general formula (I): (I) wherein R1 is hydroxy, etc.; R2 is optionally substituted lower alkyl, etc.; R3 is hydrogen, etc.; R4 is optionally substituted allylene, etc.;...
|
|
WO/2003/076416A1 |
A compound selected from those of formula (I): formula (I) wherein: - X1, X2, and X3, represent N or CR3 in which R3 is as described in the description, - G1 represents a group selected from those of formulae (i/a) and (i/b): formula (II...
|
|
WO/2003/076417A2 |
A compound selected from those of formula (I) wherein: X1, X2, and X3, represent N or -CR3 in which R3 is as described in the description, G1 represents a group selected from those of formulae (i/a) and (i/b) in which R4, R5, and R6 are ...
|
|
WO/2003/074008A2 |
The present invention encompasses compounds of formula (II); as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ...
|
|
WO/2003/073986A2 |
The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ ...
|
|
WO/2003/074523A2 |
The invention concerns macrocyclic high-relaxivity gadolinium chelate oligomers of formula: W (A)m, wherein W, A and m are such as defined in Claim 1, and their use as contrast product with vascular remanence for magnetic resonance imaging.
|
|
WO/2003/072535A2 |
This present invention relates to prodrug compounds of the formula (Y) and pharmaceutical salts thereof: where RN, R1, R2, R3R4 and RC are defined herein, which are useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2003/066577A1 |
N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pat...
|
|
WO/2003/066607A1 |
Compounds of the Formula (I) wherein T represents a group, Q represents a group, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 are as defined in the description, m represents 0, 1, 2 or 3, n represents 0 or 1, A represents alkylene, proce...
|
|
WO/2003/066646A2 |
Macrocyclic module compositions are made from cyclic synthons. The macrocyclic module structures are prepared by stepwise or concerted schemes which couple synthons in a closed ring. The macrocyclic module structures may have a pore of n...
|
|
WO/2003/066565A1 |
The invention relates to deuterated biphenyl derivatives and deuterated precursors for the production of said compounds. Deuterated biphenyl derivatives are important intermediate products in the synthesis of medicaments which can, for e...
|
|
WO/2003/066606A1 |
The invention relates to new forms of salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt. (Formula I).
|
|
WO/2003/065789A2 |
N-Biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pa...
|
|
WO/2003/066673A1 |
The invention relates to new basic amino acid derivatives of general formulae I, II and III, and the preparation and use thereof in treatment of pain. The compounds have histogranin-like antinociceptive, morphine potentiating and COX-2 i...
|
|
WO/2003/064369A1 |
It is intended to provide compounds represented by the following general formula (I) which have a high affinity for human thyroid hormone receptors, in particular, human thyroid hormone receptor β, medicinal compositions containing the ...
|
|
WO/2003/063576A2 |
Arylsulfonamidobenzyl alcohols, amines and sulfonamides are provided which are useful in treating lipid disorders, metabolic diseases and cell-proliferative diseases.
|
|
WO/2003/062248A2 |
The present invention encompasses compounds of Formula (I) as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ a...
|
|
WO/2003/055850A1 |
Novel compounds having an effect of inhibiting the production/secretion of a β-amyloid protein. Namely, compounds having various substituents as represented by the following general formula (1), salts thereof and solvates of the same: (1)
|
|
WO/2003/053912A1 |
There is provided a series of novel $g(a)-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R?1¿, R?2¿ and R?3¿ are defined herein, which are inhibitors of $g(b)-amyloid peptide ($g(b)-AP) production and are useful in t...
|
|
WO/2003/053368A2 |
The invention relates to compounds, pharmaceutical compositions and use of compounds of the general formula (I), or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.
|
|
WO/2003/051841A2 |
Carbamates and related compounds of formula R1 R2NCO-Y or R1 R2NCS-Y wherein R1 and R2 are hydrogen, alkyl, aryl, heteroaryl or may together form a piperidine, piperazine, morpholine or other heterocyclic ring, are inhibitors of hormone ...
|
|
WO/2003/051842A2 |
Carbamates and related compounds of formula R1R2NCO-Y or R1R2NCS-Y wherein R1 and R2 may form a ring, are inhibitors of hormone sensitive lipase and are useful for the treatment of any disorder where it is desirable to modulate the plasm...
|
|
WO/2003/051357A1 |
Novel compounds of formula (I), which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment of any disea...
|
|
WO/2003/048109A1 |
Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
|
|
WO/2003/048135A1 |
This invention relates to novel amorphous losartan potassium, novel losartan potassium in a crystalline form that is a hydrate, novel crystalline losartan potassium Form IV and solvates thereof, novel crystalline losartan potassium Form ...
|
|
WO/2003/040096A2 |
Disclosed are compounds of the formula (I), wherein the variables RN, RC, R1, R25, R2, and R3 are as defined herein. These compounds have activity as inhibitors of betasecretase and are therefore useful in treating a variety of discorder...
|
|
WO/2003/037328A1 |
The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II...
|
|
WO/2003/035626A2 |
The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, ...
|
|
WO/2003/035627A1 |
The present invention relates to compounds of the formula (1)and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c. d, R?1¿, R?2¿, R?3¿, R?4¿ and R?5¿ are as defined herein. Moreover, the present invention is also...
|
|
WO/2003/033476A1 |
A compound of formula (Ia) comprising a pharmaceutically acceptable salt or solvate thereof, formulations, processes of preparing, and methods of administering to mammals are provided
|
|
WO/2003/033479A1 |
The invention relates to a method for the Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Imaging of a substrate molecule different from water wherein the NMR signal is enhanced by a reversible binding of the substrate mol...
|
|
WO/2003/033480A1 |
The invention thus provides compounds of formula (I), a salt, or solvate thereof.
|
|
WO/2003/030937A1 |
Preventives and&sol or remedies for diseases, which are induced, worsened or made to recrudesce by stressors, comprising mitochondrial benzodiazepine receptor (MBR) antagonists such as compounds represented by the following general formu...
|
|
WO/2003/029229A1 |
A method of stably storing a tetrazolium compound. It comprises storing the tetrazolium compound in the presence of sodium azide. The proportion of the tetrazolium compound to the sodium azide, (A:B), is from 1:0.02 to 1:6.2. When the te...
|
|
WO/2003/029228A1 |
The invention relates to a method of preparing nitrogen macrocycles having formula (I). The inventive method comprises a step involving the reaction of compounds (II) and (III) in order to form a compound having formula (IV). Said compou...
|
|
WO/2003/027632A2 |
A strategy for drug-screening is based on cells that are isogenic except for a gene of interest. Each cell can be tranfected with a vector that encodes a different fluorescent protein that can be differentially detected to monitor cell g...
|
|
WO/2003/027081A2 |
Novel ligands for the HisB10 Zn?2+¿ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.
|
|
WO/2003/027082A1 |
A process of preparing bis-(1(2)H-tetrazol-5-yl)-amine monohydrate is provided including combining a dicyanamide salt, an azide salt and water to form a first reaction mixture, adding a solution of a first strong acid characterized as ha...
|
|
WO/2003/026668A1 |
Therapeutic methods for the prevention and treatment of ophthalmologic conditions are described, the methods including administering to a subject in need thereof a selective inhibitor of inducible nitric oxide synthase.
|
|
WO/2003/026638A1 |
Therapeutic methods for the prevention and treatment of neurodegenerative conditions are described, the methods including administering to a subject in need thereof a neuroprotective effective amount of a selective inhibitor of inducible...
|
|
WO/2003/024448A2 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds e.g. (1) and methods for inhibiting deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell p...
|
|
WO/2003/024390A2 |
A hydroxyeicosenoic acid analog represented by the following Formula (I), the bond $m(Z) represents a cis-vinylene group or an ethynylene group; Y represents CH?2¿, O or S(O)?p¿ wherein p is 0, 1 or 2; m represents an integer of 1 to 4...
|
